Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Quoted Neurology Digital Health

QUOTED. 31 January 2020. Rafael Carbunaru.

  • News

Executive Summary

Boston Scientific recently presented encouraging results of its COMBO study and discussed its partnership with IBM Health using digital health technologies and algorithms to gain an objective understanding of pain. See what Rafael Carbunaru, VP of R&D at Boston Scientific's neuromodulation division, said about it here.

"We believe that the typical measure of a 'sad face and happy face' doesn’t really describe pain. Our vision is to develop algorithms that will make our therapies smarter and autonomous to adapt with the patient’s needs." – Rafael Carbunaru, VP of R&D, Boston Scientific's neuromodulation division

Click here for a free trial of Medtech Insight

Table

View full table

Related Content

Medtech Insight

Topics

Tags:
Quoted Neurology Digital Health
Latest Headlines

FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility

‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports

Behavioral Health Company Two Chairs Secures $72M In Equity And Debt Infusion

Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations

See All
UsernamePublicRestriction

Register

MT126187

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By